Contacts

Tanja Eichkorn, MD

CONTACT

06221 56 tanja.eichkorn@med.uni-heidelbeg.de

Adriane Hommertgen, Phd

CONTACT

06221 56 adriane.hommertgen@med.uni-heidelberg.de

Sponsors

Lead Sponsor

University Hospital Heidelberg

In the present multicenter study, the benefit of SRS compared to conventional whole brain radiotherapy, each combined with best supportive care or best supportive care only, in patients with 4-15 brain metastases is to be prospectively investigated. The effect will be measured using quality-adjusted life-years (QUALY). Quality of life and overall survival are therefore primary endpoints. Secondary endpoints are the ability to perform basic activities of daily life (Barthel (ADL) index), progression-free survival, local and locoregional progression-free survival, extracranial progression, toxicity and its treatment, the recording of postherapeutic radiation-induced brain lesions (RIBL), long-term cognitive function, a possible salvage therapy as well as death from brain metastases. Furthermore, die CyberChallenge trial is linked to a translational program via BUB2 study. The BUB2 study conducts biobanking of blood, urine and resection or biopsy material, if available, as well as collects imaging material. This is to find diagnostic and prognostic biomarkers in our cancer patients via analyzing genetic, epigenetic and protein expression patterns as well as radiomics and correlating them to clinical data and therefore further push individualized patient care in brain metastases forward.

Related studies

RECRUITINGPhase 1/2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more

RECRUITING

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

NCT07363252 · EGFR-mutated NSCLC

RECRUITINGPhase 2

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507 · Central Nervous System Cancer, Brain Metastases

RECRUITINGPhase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

RECRUITINGPhase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more

View all related studies →

The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial snapshot

Condition

Locations shown

For caregivers